These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 22532859)

  • 61. Performing Gadoxetic Acid-Enhanced MRI After CT for Guiding Curative Treatment of Early-Stage Hepatocellular Carcinoma: A Cost-Effectiveness Analysis.
    Suh CH; Kim KW; Park SH; Kim SY; Woo DC; Shin S; Pyo J; Shinagare AB; Ramaiya NH; Lim YS
    AJR Am J Roentgenol; 2018 Feb; 210(2):W63-W69. PubMed ID: 29091004
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Clinical impact of 11C-Pittsburgh compound-B positron emission tomography in addition to magnetic resonance imaging and single-photon emission computed tomography on diagnosis of mild cognitive impairment to Alzheimer's disease.
    Kitajima K; Abe K; Takeda M; Yoshikawa H; Ohigashi M; Osugi K; Koyama H; Yamakado K
    Medicine (Baltimore); 2021 Jan; 100(3):e23969. PubMed ID: 33545981
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Transcranial magnetic stimulation and amyloid markers in mild cognitive impairment: impact on diagnostic confidence and diagnostic accuracy.
    Padovani A; Benussi A; Cotelli MS; Ferrari C; Cantoni V; Dell'Era V; Turrone R; Paghera B; Borroni B
    Alzheimers Res Ther; 2019 Dec; 11(1):95. PubMed ID: 31787103
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Amyloid-β misfolding as a plasma biomarker indicates risk for future clinical Alzheimer's disease in individuals with subjective cognitive decline.
    Stockmann J; Verberk IMW; Timmesfeld N; Denz R; Budde B; Lange-Leifhelm J; Scheltens P; van der Flier WM; Nabers A; Teunissen CE; Gerwert K
    Alzheimers Res Ther; 2020 Dec; 12(1):169. PubMed ID: 33357241
    [TBL] [Abstract][Full Text] [Related]  

  • 65. The ROSAS Cohort: A Prospective, Longitudinal Study of Biomarkers for Alzheimer's Disease. Strategy, Methods and Initial Results.
    de Mauléon A; Soto M; Kiyasova V; Delrieu J; Guignot I; Galtier S; Lilamand M; Cantet C; Lala F; Sastre N; Andrieu S; Pueyo M; Ousset PJ; Vellas B
    J Prev Alzheimers Dis; 2017; 4(3):183-193. PubMed ID: 29182709
    [TBL] [Abstract][Full Text] [Related]  

  • 66. A Community-Based Study Identifying Metabolic Biomarkers of Mild Cognitive Impairment and Alzheimer's Disease Using Artificial Intelligence and Machine Learning.
    Yilmaz A; Ustun I; Ugur Z; Akyol S; Hu WT; Fiandaca MS; Mapstone M; Federoff H; Maddens M; Graham SF
    J Alzheimers Dis; 2020; 78(4):1381-1392. PubMed ID: 33164929
    [TBL] [Abstract][Full Text] [Related]  

  • 67. What is the clinical impact of cerebrospinal fluid biomarkers on final diagnosis and management in patients with mild cognitive impairment in clinical practice? Results from a nation-wide prospective survey in France.
    Cognat E; Mouton Liger F; Troussière AC; Wallon D; Dumurgier J; Magnin E; Duron E; Gabelle A; Croisile B; de la Sayette V; Jager A; Blanc F; Bouaziz-Amar E; Miguet-Alfonsi C; Quillard M; Schraen S; Philippi N; Beaufils E; Pasquier F; Hannequin D; Robert P; Hugon J; Paquet C;
    BMJ Open; 2019 May; 9(5):e026380. PubMed ID: 31152032
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Diagnostic and Prognostic Value of the Combination of Two Measures of Verbal Memory in Mild Cognitive Impairment due to Alzheimer's Disease.
    Sala I; Illán-Gala I; Alcolea D; Sánchez-Saudinós MB; Salgado SA; Morenas-Rodríguez E; Subirana A; Videla L; Clarimón J; Carmona-Iragui M; Ribosa-Nogué R; Blesa R; Fortea J; Lleó A
    J Alzheimers Dis; 2017; 58(3):909-918. PubMed ID: 28527215
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Multicenter Tract-Based Analysis of Microstructural Lesions within the Alzheimer's Disease Spectrum: Association with Amyloid Pathology and Diagnostic Usefulness.
    Teipel SJ; Kuper-Smith JO; Bartels C; Brosseron F; Buchmann M; Buerger K; Catak C; Janowitz D; Dechent P; Dobisch L; Ertl-Wagner B; Fließbach K; Haynes JD; Heneka MT; Kilimann I; Laske C; Li S; Menne F; Metzger CD; Priller J; Pross V; Ramirez A; Scheffler K; Schneider A; Spottke A; Spruth EJ; Wagner M; Wiltfang J; Wolfsgruber S; Düzel E; Jessen F; Dyrba M;
    J Alzheimers Dis; 2019; 72(2):455-465. PubMed ID: 31594223
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Combined use of biochemical and volumetric biomarkers to assess the risk of conversion of mild cognitive impairment to Alzheimer's disease.
    Nesteruk M; Nesteruk T; Styczyńska M; Mandecka M; Barczak A; Barcikowska M
    Folia Neuropathol; 2016; 54(4):369-374. PubMed ID: 28139818
    [TBL] [Abstract][Full Text] [Related]  

  • 71. [The new 2011 recommendations of the National Institute on Aging and the Alzheimer's Association on diagnostic guidelines for Alzheimer's disease: Preclinal stages, mild cognitive impairment, and dementia].
    Croisile B; Auriacombe S; Etcharry-Bouyx F; Vercelletto M; ;
    Rev Neurol (Paris); 2012 Jun; 168(6-7):471-82. PubMed ID: 22579080
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Incident Cerebral Microbleeds Detected by Susceptibility Weight-Imaging Help to Identify Patients with Mild Cognitive Impairment Progressing to Alzheimer's Disease.
    Basselerie H; Bracoud L; Zeestraten E; Bouguen E; Kiyasova V; Pueyo M; Cognard C; Dumas H; Gramada R; Ousset PJ; Vellas B; Bonneville F
    J Alzheimers Dis; 2017; 60(1):253-262. PubMed ID: 28826188
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Diagnostic Accuracy of MRI Visual Rating Scales in the Diagnosis of Early Onset Cognitive Impairment.
    Falgàs N; Balasa M; Bargalló N; Borrego-Écija S; Ramos-Campoy O; Fernández-Villullas G; Bosch B; Olives J; Tort-Merino A; Antonell A; Castellví M; Allen IE; Sánchez-Valle R; Lladó A
    J Alzheimers Dis; 2020; 73(4):1575-1583. PubMed ID: 31958089
    [TBL] [Abstract][Full Text] [Related]  

  • 74. [Using markov model to cost-effectiveness analysis of traditional Chinese medicine interference].
    Wang N; Zhang ZJ; Chang D
    Zhongguo Zhong Yao Za Zhi; 2012 Sep; 37(18):2698-701. PubMed ID: 23285912
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Screening for preclinical Alzheimer's disease: Deriving optimal policies using a partially observable Markov model.
    Önen Dumlu Z; Sayın S; Gürvit İH
    Health Care Manag Sci; 2023 Mar; 26(1):1-20. PubMed ID: 36044131
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Curriculum learning for early Alzheimer's Disease diagnosis.
    Gracias C; Silveira M
    Annu Int Conf IEEE Eng Med Biol Soc; 2022 Jul; 2022():4777-4780. PubMed ID: 36086405
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Early intervention in Alzheimer's disease: a health economic study of the effects of diagnostic timing.
    Barnett JH; Lewis L; Blackwell AD; Taylor M
    BMC Neurol; 2014 May; 14():101. PubMed ID: 24885474
    [TBL] [Abstract][Full Text] [Related]  

  • 78. The role of magnetic resonance imaging in the diagnosis and prognosis of dementia.
    Živanović M; Aracki Trenkić A; Milošević V; Stojanov D; Mišić M; Radovanović M; Radovanović V
    Biomol Biomed; 2023 Mar; 23(2):209-224. PubMed ID: 36453893
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Brain Glucose Activated MRI Contrast Agent for Early Diagnosis of Alzheimer's Disease.
    Liu J; Chen C; Chen H; Huang C; Ren Q; Sun M; Tao J; Lin B; Zhao P
    Anal Chem; 2022 Nov; 94(46):16213-16221. PubMed ID: 36367962
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Identification of Alzheimer's Disease by Imaging: A Comprehensive Review.
    T P; V S
    Int J Environ Res Public Health; 2023 Jan; 20(2):. PubMed ID: 36674027
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.